GENZYME CORP Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 67 rows in 2007. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2007-12-17: Reporting owner WYZGA MICHAEL S; Form 4; Security Genzyme ISO stock option (right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2007-12-17: Reporting owner WYZGA MICHAEL S; Form 4; Security Genzyme ISO stock option (right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2007-12-17: Reporting owner SMITH ALAN E; Form 4; Security Genzyme NQ stock option (right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2007-11-29: Reporting owner DZAU VICTOR J; Form 4; Security Genzyme DOP Stock Option (right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2007-12-17 | WYZGA MICHAEL S Officer (Executive VP and CFO) | 4 | Genzyme ISO stock option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,000 0 owned after | $22.06 exercise price | 2007-12-18 | |
| 2007-12-17 | WYZGA MICHAEL S Officer (Executive VP and CFO) | 4 | Genzyme ISO stock option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −140 0 owned after | $64.66 exercise price | 2007-12-18 | |
| 2007-12-17 | SMITH ALAN E Officer (Senior Vice President) | 4 | Genzyme NQ stock option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −20,000 83,282 owned after | $29.44 exercise price | 2007-12-18 | |
| 2007-11-29 | DZAU VICTOR J Director | 4 | Genzyme DOP Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,000 0 owned after | $62.98 exercise price | 2007-11-30 | |
| 2007-11-21 | DZAU VICTOR J Director | 4 | Genzyme DOP Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 5,000 owned after | $62.98 exercise price | 2007-11-26 | |
| 2007-11-15 | CARPENTER ROBERT J Director | 4 | Genzyme DOP stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −18,543 0 owned after | $18.61 exercise price | 2007-11-16 | |
| 2007-11-13 | DZAU VICTOR J Director | 4 | Genzyme DOP NQ Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,000 14,000 owned after | $58.50 exercise price | 2007-11-15 | |
| 2007-11-13 | DZAU VICTOR J Director | 4 | Genzyme DOP Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −9,000 15,000 owned after | $62.98 exercise price | 2007-11-15 | |
| 2007-11-02 | CARPENTER ROBERT J Director | 4 | Genzyme DOP stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,219 18,543 owned after | $18.61 exercise price | 2007-11-06 | |
| 2007-11-01 | CARPENTER ROBERT J Director | 4 | Genzyme DOP stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −17,324 19,762 owned after | $18.61 exercise price | 2007-11-05 | |
| 2007-10-30 | GEMAYEL GEORGES Officer (Executive Vice President) | 4 | Genzyme NQ stock option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −37,500 37,500 owned after | $46.39 exercise price | 2007-11-02 | |
| 2007-10-30 | TERMEER HENRI A Director, Officer (Chmn, President and CEO) | 4 | Genzyme NQ stock option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −50,723 0 owned after | $29.44 exercise price | 2007-10-31 | |
| 2007-10-29 | TERMEER HENRI A Director, Officer (Chmn, President and CEO) | 4 | Genzyme NQ stock option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −158,026 50,723 owned after | $29.44 exercise price | 2007-10-31 | |
| 2007-10-26 | TERMEER HENRI A Director, Officer (Chmn, President and CEO) | 4 | Genzyme NQ stock option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −257,053 208,749 owned after | $29.44 exercise price | 2007-10-29 | |
| 2007-10-25 | MCGILLICUDY CORNELIUS III Director | 4 | Genzyme DOP stock option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −24,000 0 owned after | $41.44 exercise price | 2007-10-29 | |
| 2007-10-15 | SMITH SANDFORD D Officer (Executive Vice President) | 4 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −25,000 16,700 owned after | $46.24 exercise price | 2007-10-17 | |
| 2007-10-15 | COLLIER EARL M JR Officer (Executive Vice President) | 4 | Genzyme NQ stock option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −32,400 16,200 owned after | $43.90 exercise price | 2007-10-17 | |
| 2007-10-10 | SMITH SANDFORD D Officer (Executive Vice President) | 4 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,300 41,700 owned after | $46.24 exercise price | 2007-10-12 | |
| 2007-10-10 | SMITH SANDFORD D Officer (Executive Vice President) | 4 | Genzyme NQ stock option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −21,700 22,800 owned after | $43.90 exercise price | 2007-10-12 | |
| 2007-05-31 | GEMAYEL GEORGES Officer (Executive Vice President) | 4 | Genzyme ISO stock option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,277 2,277 owned after | $43.90 exercise price | 2007-06-01 | |
| 2007-05-24 | CSIMMA ZOLTAN A Officer (Senior VP, Human Resources) | 4 | Genzyme ISO stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,040 8,040 owned after | $62.16 exercise price | 2007-05-29 | |
| 2007-05-24 | CSIMMA ZOLTAN A Officer (Senior VP, Human Resources) | 4 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +9,460 9,460 owned after | $62.16 exercise price | 2007-05-29 | |
| 2007-05-24 | WYZGA MICHAEL S Officer (Executive VP and CFO) | 4 | Genzyme ISO stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,040 8,040 owned after | $62.16 exercise price | 2007-05-29 | |
| 2007-05-24 | WYZGA MICHAEL S Officer (Executive VP and CFO) | 4 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +36,960 36,960 owned after | $62.16 exercise price | 2007-05-29 | |
| 2007-05-24 | WIRTH PETER Officer (Executive Vice President) | 4 | Genzyme ISO stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,040 8,040 owned after | $62.16 exercise price | 2007-05-29 | |
| 2007-05-24 | WIRTH PETER Officer (Executive Vice President) | 4 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +36,960 36,960 owned after | $62.16 exercise price | 2007-05-29 | |
| 2007-05-24 | SMITH SANDFORD D Officer (Executive Vice President) | 4 | Genzyme ISO stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,040 8,040 owned after | $62.16 exercise price | 2007-05-29 | |
| 2007-05-24 | SMITH SANDFORD D Officer (Executive Vice President) | 4 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +36,960 36,960 owned after | $62.16 exercise price | 2007-05-29 | |
| 2007-05-24 | SMITH ALAN E Officer (Senior Vice President) | 4 | Genzyme ISO stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,040 8,040 owned after | $62.16 exercise price | 2007-05-29 | |
| 2007-05-24 | SMITH ALAN E Officer (Senior Vice President) | 4 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +16,210 16,210 owned after | $62.16 exercise price | 2007-05-29 | |
| 2007-05-24 | MOSCICKI RICHARD A Officer (Senior Vice President) | 4 | Genzyme ISO stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,040 8,040 owned after | $62.16 exercise price | 2007-05-29 | |
| 2007-05-24 | MOSCICKI RICHARD A Officer (Senior Vice President) | 4 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +16,210 16,210 owned after | $62.16 exercise price | 2007-05-29 | |
| 2007-05-24 | GEMAYEL GEORGES Officer (Executive Vice President) | 4 | Genzyme ISO stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,824 4,824 owned after | $62.16 exercise price | 2007-05-29 | |
| 2007-05-24 | GEMAYEL GEORGES Officer (Executive Vice President) | 4 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,176 40,176 owned after | $62.16 exercise price | 2007-05-29 | |
| 2007-05-24 | COLLIER EARL M JR Officer (Executive Vice President) | 4 | Genzyme ISO stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,040 8,040 owned after | $62.16 exercise price | 2007-05-29 | |
| 2007-05-24 | COLLIER EARL M JR Officer (Executive Vice President) | 4 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +36,960 36,960 owned after | $62.16 exercise price | 2007-05-29 | |
| 2007-05-24 | TERMEER HENRI A Director, Officer (Chmn, President and CEO) | 4 | Genzyme ISO stock option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,040 8,040 owned after | $62.16 exercise price | 2007-05-25 | |
| 2007-05-24 | TERMEER HENRI A Director, Officer (Chmn, President and CEO) | 4 | Genzyme NQ Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +191,960 191,960 owned after | $62.16 exercise price | 2007-05-25 | |
| 2007-05-24 | SYRON RICHARD F/CA Director | 4 | Genzyme DEP NQ Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,000 15,000 owned after | $62.16 exercise price | 2007-05-25 | |
| 2007-05-24 | MCGILLICUDY CORNELIUS III Director | 4 | Genzyme DEP NQ Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,000 15,000 owned after | $62.16 exercise price | 2007-05-25 | |
| 2007-05-24 | DZAU VICTOR J Director | 4 | Genzyme DEP NQ Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,000 15,000 owned after | $62.16 exercise price | 2007-05-25 | |
| 2007-05-24 | COONEY CHARLES L Director | 4 | Genzyme DEP NQ Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,000 15,000 owned after | $62.16 exercise price | 2007-05-25 | |
| 2007-05-24 | CARPENTER ROBERT J Director | 4 | Genzyme DEP NQ Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,000 15,000 owned after | $62.16 exercise price | 2007-05-25 | |
| 2007-05-24 | BOUDREAUX GAIL Director | 4 | Genzyme DEP NQ Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,000 15,000 owned after | $62.16 exercise price | 2007-05-25 | |
| 2007-05-24 | BERTHIAUME DOUGLAS A Director | 4 | Genzyme DEP NQ Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,000 15,000 owned after | $62.16 exercise price | 2007-05-25 | |
| 2007-02-07 holding as of filing | SMITH SANDFORD D Officer (Executive Vice President) | 3/A | Genzyme ISO stock option (right to buy) Derivative · Direct | Holding | $837.07 exercise price | 2007-02-07 | ||
| 2007-02-07 holding as of filing | SMITH SANDFORD D Officer (Executive Vice President) | 3/A | Genzyme ISO stock option (right to buy) Derivative · Direct | Holding | $124.69 exercise price | 2007-02-07 | ||
| 2007-02-07 holding as of filing | SMITH SANDFORD D Officer (Executive Vice President) | 3/A | Genzyme ISO stock option (right to buy) Derivative · Direct | Holding | $392.13 exercise price | 2007-02-07 | ||
| 2007-02-07 holding as of filing | SMITH SANDFORD D Officer (Executive Vice President) | 3/A | Genzyme ISO stock option (right to buy) Derivative · Direct | Holding | $32.52 exercise price | 2007-02-07 | ||
| 2007-02-07 holding as of filing | SMITH SANDFORD D Officer (Executive Vice President) | 3/A | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $135.25 exercise price | 2007-02-07 | ||
| 2007-02-07 holding as of filing | SMITH SANDFORD D Officer (Executive Vice President) | 3/A | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $837.07 exercise price | 2007-02-07 | ||
| 2007-02-07 holding as of filing | SMITH SANDFORD D Officer (Executive Vice President) | 3/A | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $595.75 exercise price | 2007-02-07 | ||
| 2007-02-07 holding as of filing | SMITH SANDFORD D Officer (Executive Vice President) | 3/A | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $124.69 exercise price | 2007-02-07 | ||
| 2007-02-07 holding as of filing | SMITH SANDFORD D Officer (Executive Vice President) | 3/A | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $392.13 exercise price | 2007-02-07 | ||
| 2007-02-07 holding as of filing | SMITH SANDFORD D Officer (Executive Vice President) | 3/A | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $95.76 exercise price | 2007-02-07 | ||
| 2007-02-07 holding as of filing | SMITH SANDFORD D Officer (Executive Vice President) | 3/A | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $467.56 exercise price | 2007-02-07 | ||
| 2007-02-07 holding as of filing | SMITH SANDFORD D Officer (Executive Vice President) | 3/A | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $223.18 exercise price | 2007-02-07 | ||
| 2007-02-07 holding as of filing | SMITH SANDFORD D Officer (Executive Vice President) | 3/A | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $226.75 exercise price | 2007-02-07 | ||
| 2007-02-07 holding as of filing | SMITH SANDFORD D Officer (Executive Vice President) | 3/A | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $53.47 exercise price | 2007-02-07 | ||
| 2007-02-07 holding as of filing | SMITH SANDFORD D Officer (Executive Vice President) | 3/A | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $126.59 exercise price | 2007-02-07 | ||
| 2007-02-07 holding as of filing | SMITH SANDFORD D Officer (Executive Vice President) | 3/A | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $274.31 exercise price | 2007-02-07 | ||
| 2007-02-07 holding as of filing | SMITH SANDFORD D Officer (Executive Vice President) | 3/A | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $85.74 exercise price | 2007-02-07 | ||
| 2007-02-07 holding as of filing | SMITH SANDFORD D Officer (Executive Vice President) | 3/A | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $41.50 exercise price | 2007-02-07 | ||
| 2007-02-07 holding as of filing | SMITH SANDFORD D Officer (Executive Vice President) | 3/A | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $32.52 exercise price | 2007-02-07 | ||
| 2007-02-07 holding as of filing | SMITH SANDFORD D Officer (Executive Vice President) | 3/A | Genzyme NQ Stock Option (right to buy) Derivative · Direct | Holding | $46.24 exercise price | 2007-02-07 | ||
| 2007-02-07 holding as of filing | SMITH SANDFORD D Officer (Executive Vice President) | 3/A | Genzyme NQ stock option (right to buy) Derivative · Direct | Holding | $43.90 exercise price | 2007-02-07 | ||
| 2007-02-07 holding as of filing | SMITH SANDFORD D Officer (Executive Vice President) | 3/A | Genzyme NQ Stock Option (right to buy) Derivative · Direct | Holding | $62.98 exercise price | 2007-02-07 |